Single-Dose HPV Vaccine Evaluation Consortium

Related program: Center for Vaccine Innovation and Access

Since 2018, the Single-Dose HPV Vaccine Evaluation Consortium, coordinated by PATH, has gathered and evaluated data from clinical trials, observational studies, and modeling analyses regarding the value of a single-dose HPV vaccination schedule to protect against cervical cancer.

Results are emerging from several clinical trials evaluating the ability of a single dose of HPV vaccine to elicit a strong immune response against incident and persistent HPV infections, which are the necessary prerequisites to development of cervical lesions and in the longer term, cervical cancer.

The data accumulated to date support the World Health Organization (WHO) endorsement of a single-dose HPV vaccination schedule for substantially reducing the incidence of HPV-attributable cervical precancer and cancer for the primary target of girls aged 9-14 years old and for young women aged 15-20 years old.

Explore and share the evidence using the resources below.

Resources from the Single-Dose HPV Vaccine Evaluation Consortium

Frequently asked questions about single-dose HPV vaccination
This four-page FAQ document provides answers to common questions on current evidence and policy landscape for single-dose HPV vaccination.

Fact sheet: Evidence on single-dose HPV vaccination
This two-page brief provides a snapshot of the evidence supporting WHO’s endorsement of a single-dose HPV vaccination schedule.

Slide deck:
This PowerPoint deck outlines the evidence base in support of a single-dose vaccination schedule. Use the presentation as a guide for meetings with key decision-makers.

2022 Evidence Review:
The 2022 Evidence Review by the Single-Dose HPV Evaluation Consortium collated, synthesized, and evaluated evidence that contributed to the WHO SAGE endorsement of a single-dose HPV vaccination schedule in the primary target group.

  • Read the five-page general summary.
  • Read the 30-page technical synthesis of the HPV Single Dose Consortium’s full review of current, published evidence relevant to single-dose HPV vaccination. This includes immunogenicity, efficacy and effectiveness; identification of gaps in the evidence; and forthcoming evidence.
  • Read the full text of the Evidence Review.

External resources

HPV Vaccine Schedule Optimization Guide, October 2023

World Health Organization updated position paper on HPV vaccination schedules, December 2022

WHO Strategic Advisory Group of Experts on Immunization (SAGE) endorsement of a single-dose HPV vaccination schedule, April 2022

Publications on single-dose HPV vaccination